Heron Therapeutics reported $38K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Eisai JPY 16.7B 8.03B Sep/2026
Emergent BioSolutions USD -218M 69.9M Jun/2023
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 2.57B 2.56B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Veracyte USD 18.02M 5.94M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026